Suggestions
Andreas Wallnoefer
General Partner BioMedPartners Ltd. Board Director in Biotech
Andreas Wallnoefer is a prominent figure in the biotechnology and pharmaceutical sectors, currently serving as a General Partner at BioMedPartners Ltd., a leading Swiss venture capital firm specializing in biotech investments. With over 25 years of experience, he has held significant roles in both corporate and investment environments.
Career Overview
-
Early Career at Roche: Wallnoefer began his career at Roche in 1992, where he climbed the ranks to hold various executive positions within the R&D division. His roles included Head of Clinical Research and Global Head of Cardiovascular & Metabolism R&D. He was instrumental in integrating Roche and Genentech's clinical development organizations following Roche's acquisition of Genentech in 2009.12
-
Transition to Venture Capital: In 2016, he joined BioMedPartners as General Partner, overseeing the growth and development of multiple biotech startups. His expertise in translating scientific innovations into viable products has been a hallmark of his work.34
-
Current Role: In 2021, Wallnoefer transitioned to Jeito Capital, a Paris-based private equity firm focused on biopharmaceuticals, but he continues to be recognized for his contributions at BioMedPartners.25
Contributions and Achievements
-
Board Memberships: He has served on the boards of several European biotech companies and has been involved in numerous successful product developments that have reached the market.12
-
Awards and Recognition: Wallnoefer was awarded Singapore’s Public Service Medal in 2022 for his contributions to drug development and advisory roles within the country’s healthcare sector.2
-
Educational Background: He holds a degree in clinical pharmacology and has completed an Executive MBA from IMD Business School, which further enhanced his capabilities in managing biotech investments.24
Wallnoefer's extensive background in R&D and venture capital positions him as a key player in the advancement of innovative therapies and investment strategies within the biotechnology landscape.
